Streetbeat News

Price Targets

USGO

HC Wainwright & Co. has maintained a Buy rating on US Goldmining (NASDAQ:USGO) and raised the price target from $23.5 to $24, indicating a positive outlook for the stock.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:09 am

SLE

HC Wainwright & Co. analyst Scott Buck has reiterated a Buy rating for Super League Enterprise (NASDAQ:SLE) and maintained a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:07 am

FPAY

HC Wainwright & Co. analyst Scott Buck has reiterated a Buy rating on FlexShopper (NASDAQ:FPAY) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:03 am

TNDM

RBC Capital has initiated coverage on Tandem Diabetes Care with an Outperform rating and set a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 9:57 am

ABSI

Guggenheim has initiated coverage on Absci (NASDAQ:ABSI) with a Buy rating and set a price target of $10, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 9:48 am

STTK

Needham analyst Gil Blum has downgraded Shattuck Labs (NASDAQ:STTK) from Buy to Hold, while maintaining a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 9:41 am

MGNI

Needham analyst Laura Martin has reiterated a Buy rating on Magnite (NASDAQ:MGNI) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 9:34 am

IONQ

Needham analyst Quinn Bolton has reiterated a Buy rating on IonQ (NYSE:IONQ) and maintained a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 9:31 am

RPM

RPM International Inc. is set to release its Q1 earnings on Oct. 2, with expectations of $1.75 EPS and $2.02 billion in revenue. Recent analyst ratings show mixed sentiments, with some maintaining outperform ratings but lowering price targets, while others downgraded the stock.

Portfolio Pulse from Avi Kapoor

October 02, 2024 | 7:03 am

ARCT

Three analysts have recently provided ratings on Arcturus Therapeutics (NASDAQ:ARCT), with two being bullish and one somewhat bullish. The average 12-month price target has increased to $65.33, reflecting a 6.23% rise from the previous target. Arcturus Therapeutics, an RNA medicines company, has shown significant revenue growth and maintains a strong market position despite some financial challenges.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 9:00 pm